AstraZeneca's (AZN) novel cancer drug - Lynparza - has successfully completed another final-stage clinical trial. The drug is already approved for ovarian cancer patients, but this time proved to be better than chemotherapy in treating breast cancer patients with the BRCA gene mutation.
IC TIP:
Buy
at
4588p
The BRCA mutation was found to hugely increase a woman's chances of developing breast cancer in 2014 and since then drugs companies have been working on developing medicines that use this finding to their advantage. Lynparza is the first of this type of drug to gain approval. Broker Liberum expects sales from Lynparza and recently launched lung cancer drug Tagrisso to add 12 per cent to earnings between 2017 and 2021.